The Body’s Postal Service Has an Age Problem, and Somebody Wants to Sell You Stamps
This is a narrative review, not an experiment. Four authors from dental and periodontal departments survey roughly 150 laboratory and clinical studies on extracellular vesicles (EVs), the tiny membrane-wrapped packages that cells use to ship proteins and RNA to one another. Their central claim is that EVs are not passive debris but active carriers of aging signals in both directions: vesicles from young or stem-cell sources reduce senescence markers, restore mitochondrial and autophagic function, and improve tissue repair in animals, while vesicles from aged or diseased tissue transmit inflammation, fibrosis, and insulin resistance into young recipients. The review maps these effects onto the twelve hallmarks of aging and argues EVs intersect nearly all of them at once. The evidence base it assembles is overwhelmingly preclinical.
Cells talk to each other by mail. They wrap proteins, fragments of RNA, and sometimes whole mitochondria inside membrane bubbles a hundred nanometers across, release them into blood and tissue fluid, and other cells open the package and act on the contents. For most of the time these vesicles have been known about, biologists filed them under cellular waste disposal. That view has collapsed. The mail is the message.
The idea assembled in this review is that aging is partly a corruption of this postal system. Take blood plasma from an old mouse, isolate the vesicles, inject them into a young mouse, and the young animal develops markers of aging across several organs at once: DNA damage signals, fatty liver, insulin resistance. Run the experiment backwards, giving vesicles from young or embryonic stem cells to old animals, and a long list of measurements moves the other way. Grip strength improves. Bone density rises. Ovaries produce more follicles. Kidneys show less scarring. In one study, treated mice lived about fifteen percent longer than untreated ones.
What makes this interesting rather than merely another rejuvenation claim is the specificity. Researchers have repeatedly named the single molecule doing the work, then deleted it to make the effect disappear. A small RNA called miR-155, delivered by immune-cell vesicles, attacks a protein that caps chromosomes and drives kidney cells into senescence. Knock out miR-155 and the kidney damage does not happen. A different small RNA, miR-302b, appears to release senescent cells from their frozen state. Vesicles carrying the enzyme eNAMPT restore the cellular fuel NAD across brain, muscle, retina, and pancreas.
The same finding cuts the other way, and this is the part the field underplays. Vesicles are not inherently good. Their effect depends on which cell made them and what condition that cell was in. Vesicles from aged bone marrow induce diabetes-like metabolism in young animals. Vesicles from starving muscle shut down muscle regeneration. Vesicles from infected gut lining break the intestinal barrier. A therapy built on this biology is not a drug with a known structure, it is a bulk preparation whose contents shift with the donor and the culture conditions.
Which is exactly the gap between this literature and the clinic. There is no standard method to isolate these vesicles, no agreement on what counts as a dose, and no completed human trial of EV therapy for aging anywhere in this review. Clinics are already selling exosome injections. The science supporting them has not yet been done.
Insights
Read this review for orientation, not for anything you can act on today. It contains one usable number.
Lifespan. One cited study treated mice starting at 25 months of age and extended median lifespan by 137 days, a 15.4 percent gain. Working backward from those two figures, the untreated mice lived a median of about 890 days, a normal healthy control lifespan rather than a sickly one. That matters, because rescuing unhealthy controls is the most common way a lifespan result gets inflated.
Diagnostics. Blood vesicle microRNAs separated people with mild cognitive impairment from matched controls with an accuracy score (AUC) of 0.90. In plain terms, pick one impaired and one unimpaired person at random and the test ranks them correctly 90 percent of the time. That is a large separation, roughly a Cohen’s d of 1.8.
Everything else. Every other benefit is reported as “significantly improved” with no number attached. There is no effect size for grip strength, bone density, insulin sensitivity, or cognition, in any species.
Two practical points. Exercise raises irisin-carrying vesicles that track inversely with arterial stiffness, one more mechanistic argument for training you were already doing. And commercially sold exosome injections rest on zero completed human aging trials.
Context and Source
- Open Access Paper: Understanding extracellular vesicles in antiaging
- Authors: Paras Ahmad, Nathan E. Estrin, Anton Sculean, Richard J. Miron
- Institutions: Department of Research, Advanced PRF Education, Jupiter, Florida, USA; College of Dentistry and Dental Clinics, University of Iowa, USA; Lake Erie College of Osteopathic Medicine, Bradenton, Florida, USA; Department of Periodontology, University of Bern, Switzerland (corresponding author)
- Countries: USA and Switzerland
- Journal: Periodontology 2000 (Wiley), DOI 10.1111/prd.70070
-
Article type: Narrative review, part of the journal’s “Exosomes in Oral Treatment and Beyond” series
Impact evaluation: The impact score of this journal is 17.0 (2024 Journal Impact Factor; CiteScore 15.9), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.